Middle East and North Africa Knee Cartilage Repair Market
Cartilage is a connective tissue or soft bone found in many parts of the body, and it is more prone to damage due to its flexibility. The damaged knee cartilage is observed mostly in older people and patients who have arthritis, sports players, athletes, young children, and people having other injuries. The best treatment to treat the knee cartilage is surgery. The treatment includes replacement and regeneration.
Developments in Orthopedic Field Drive MENA Knee Cartilage Repair Market
Organizations and market players are investing in the development of the orthopedic field in the Middle East and North Africa region through various means. For instance, in November 2022, Zimmer Biomet inaugurated a new Innovation Hub in Dubai to showcase its technological advancements, surgical robots, and implants. In January 2022, Zimmer Biomet expanded its office in Dubai to meet the growing demand from hospitals and clinics in the Middle East, North Africa, and Turkey (MENAT). This strategic decision by the company is expected to influence the MENA knee cartilage repair market growth in the near future.
Similarly, the number of orthopedic clinics is expanding in the region. In January 2023, Burjeel Holdings—one of the leading private healthcare service providers in MENA—collaborated with the Paley Middle East Clinic to open a new clinic in Burjeel Medical City, Abu Dhabi. The collaboration aims to provide world-class specialized orthopedic care. The new clinic will also expand the Paley Institute’s medical tourism in the MENA.
Moreover, regional companies are receiving product approvals for their developments in the field of cartilage repair. In March 2022, Israel-based CartiHeal Ltd received premarket approval from the US Food and Drug Administration (FDA) for its Agili-C implant. Agili-C is designed to treat International Cartilage Repair Society (ICRS) grade III or above knee-joint surface lesion(s). Such developments in the orthopedic field are driving the MENA knee cartilage repair market growth.
The growing technological advancements have enabled the use of AI to diagnose cartilage defects. Using AI, it is possible to identify the precise segmentation and robust assessment of chondral lesions, including diameter, shape, location, shape, and boundaries. Market players have developed AI tools and solutions for effective and efficient imaging technologies for all orthopedic segments. For instance, an Israel-based company, RSIP Vision, has developed an AI tool that accurately assesses chondral lesions in magnetic resonance imaging (MRI) scans for hips, knees, and ankles using noninvasive techniques. The AI tool offers an accurate measurement of osteochondral lesions that helps physicians evaluate the damage’s severity and select an effective treatment plan. The tool also helps in assessing the efficacy of the treatment. Such innovations are expected to drive the knee cartilage repair market as the prevalence of chondral lesions is much higher in older and young people. Moreover, articular cartilage has avascular nature, which limits its healing potential. In many cases, chondral lesions restrict athletes from participating in sports and may affect their daily activities. Therefore, the use of AI in diagnosing cartilage defects is expected to assist in choosing better treatment plans and eventually contribute to the growth of the market in the near future.
MENA Knee Cartilage Repair Market: Competitive Landscape and Key Developments
Arthrex Inc, Medical Device Business Services Inc, Zimmer Biomet Holdings Inc, Medacta Group SA, Anika Therapeutics Inc, Conmed Corp, Stryker Corp, CartiHeal Inc, Smith & Nephew Plc, and B. Braun SE are among the key companies operating in the MENA knee cartilage repair market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the MENA knee cartilage repair market.
A few of the recent developments in the MENA knee cartilage repair market are mentioned below:
- In March 2022, CartiHeal received US Food and Drug Administration Premarket Approval (PMA) for its Agili-C implant. CartiHeal Ltd. is a developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee joints. Agili-C implant helps treat certain cartilage and osteochondral defects.
- In December 2021, DePuy Synthes acquired OrthoSpin, Ltd. OrthoSpin develops and manufactures a first-of-its-kind technology—an automated strut system—which is used in conjunction with DePuy Synthes MAXFRAME Multi-Axial Correction System, an external ring fixation system. This acquisition is a clear example of Johnson & Johnson’s continued commitment to advancing innovation in the MedTech space.
